Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Soluble HLA-I in rheumatic diseases

R E Wolf1, I M Adamashvili, F B Gelder

  • 1Department of Medicine, Louisiana State University Medical Center, Shreveport 71130-3932, USA.

Human Immunology
|October 3, 1998
PubMed
Summary

Serum levels of soluble HLA Class I (sHLA-I) differ in rheumatic diseases and ethnic groups. Systemic lupus erythematosus (SLE) patients showed higher sHLA-I, with variations across ethnicities and other rheumatic conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asbestos Fiber Type and Length in Lungs of Chrysotile Textile and Production Workers: Fibers Longer than 18 μm.

Inhalation toxicology·2015
Same author

Deficits in visuospatial processing contribute to quantitative measures of freezing of gait in Parkinson's disease.

Neuroscience·2012
Same author

Standardisation in standards.

Radiation protection dosimetry·2012
Same author

Rapid Prototyping of Microfluidic Systems in Poly(dimethylsiloxane).

Analytical chemistry·2011
Same author

Trials of Live Influenza Vaccine in the Royal Air Force.

British medical journal·2010
Same author

ABO Blood Groups and Acute Respiratory Virus Disease.

British medical journal·2010

Area of Science:

  • Immunogenetics
  • Rheumatology
  • Human Genetics

Background:

  • Soluble human leukocyte antigen Class I (sHLA-I) are immune markers.
  • Ethnic variations in immune responses are documented.
  • Rheumatic diseases involve complex immune dysregulation.

Purpose of the Study:

  • To quantify serum sHLA-I levels in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), polymyositis/dermatomyositis (PM/DM), and scleroderma patients.
  • To investigate the impact of ethnic background on sHLA-I concentrations within these rheumatic disease cohorts.
  • To compare sHLA-I levels between patients and healthy individuals.

Main Methods:

  • Serum sHLA-I levels were measured using a solid-phase enzyme-linked immunoassay.
  • 385 patients with rheumatic diseases across diverse ethnic groups (American-Caucasians, African-Americans, Georgian-Caucasians) were studied.

Related Experiment Videos

  • Data were compared to 189 healthy individuals.

    • Main Results:

    • Significantly elevated sHLA-I levels were observed in SLE patients compared to healthy controls and other rheumatic diseases.
    • Georgian-Caucasian SLE patients exhibited the highest sHLA-I concentrations.
    • American-Caucasian patients with RA or scleroderma had increased sHLA-I; PM/DM patients were predominantly low secretors across ethnicities.

    Conclusions:

    • Secretion mechanisms for sHLA-I vary among different rheumatic diseases and ethnic populations.
    • Observed genetic differences in sHLA-I secretion may correlate with ethnic and pathophysiological distinctions in these rheumatic conditions.
    • Further research into ethnic and genetic factors influencing sHLA-I is warranted for understanding disease pathogenesis.